1-3 of 3
Sandra Klein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Qing Li, Sandra Klein, Claire Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 586–589.
https://doi.org/10.1182/blood-2022-158147
Published: 2022
Journal Articles

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas
Journal: Blood
Blood (2022) 140 (Supplement 1): 9659–9662.
https://doi.org/10.1182/blood-2022-157735
Published: 2022
Journal Articles

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Clinical Trials & Observations
Lorenzo Falchi, Helen Ma, Sandra Klein, Jennifer K. Lue, Francesca Montanari, Enrica Marchi, Changchun Deng, Hye A. Kim, Aishling Rada, Alice T. Jacob, Cristina Kinahan, Mark M. Francescone, Craig R. Soderquist, David C. Park, Govind Bhagat, Renu Nandakumar, Daniel Menezes, Luigi Scotto, Lubomir Sokol, Andrei R. Shustov, Owen A. O’Connor
Journal: Blood
Blood (2021) 137 (16): 2161–2170.
https://doi.org/10.1182/blood.2020009004
Published: 2021
Includes: Supplemental data